IDH1 Mutation Clinical Trials

4 recruiting

IDH1 Mutation Trials at a Glance

6 actively recruiting trials for idh1 mutation are listed on ClinicalTrialsFinder across 6 cities in 17 countries. The largest study group is Phase 2 with 5 trials, with the heaviest enrollment activity in Durham, Houston, and Boston. Lead sponsors running idh1 mutation studies include Institut de Recherches Internationales Servier, Institute of Hematology & Blood Diseases Hospital, China, and Justin Watts, MD.

Browse idh1 mutation trials by phase

Treatments under study

About IDH1 Mutation Clinical Trials

Looking for clinical trials for IDH1 Mutation? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new IDH1 Mutation trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about IDH1 Mutation clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Phase 2

Ivosidenib as Post-HSCT Maintenance for AML

Acute Myeloid Leukemia (AML)IDH1 MutationHematopoietic Stem Cell Transplant (HSCT)
Massachusetts General Hospital75 enrolled4 locationsNCT06707493
Recruiting
Phase 2

Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy

Acute Myeloid LeukemiaIDH1 Mutation
Justin Watts, MD16 enrolled1 locationNCT06782542
Recruiting
Phase 1Phase 2

Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML

TreatmentAMLIDH1 Mutation
Institute of Hematology & Blood Diseases Hospital, China29 enrolled1 locationNCT06611839
Recruiting
Phase 3

Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen

Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
Servier Bio-Innovation LLC136 enrolled114 locationsNCT06127407
Recruiting
Phase 1Phase 2

Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation

Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation
Institut de Recherches Internationales Servier52 enrolled37 locationsNCT06501625
Recruiting
Phase 2

Study of Olutasidenib and Temozolomide in HGG

Metastatic Brain TumorIDH1 MutationAstrocytoma, Grade IV+16 more
Rigel Pharmaceuticals60 enrolled18 locationsNCT06161974